Study #2022-0916
A phase 1, first-in-human study of JNJ-80948543, a T-cell redirecting antibody, in participants with NHL and CLL
MD Anderson Study Status
Enrolling
Treatment Agent
JNJ-80948543
Description
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D\[s\]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize the safety of JNJ-80948543 at the putative RP2D(s) in Part B (Cohort Expansion).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Study phase:
Phase I
Physician name:
Michael Wang
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.